Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
AstraZeneca AZN stock has risen 13.6% in the past six months, outperforming an increase of 7.1% for the industry. AstraZeneca ...
In several short films directed by Reed Morano, the “What science can do” campaign features stories from a cancer patient and an asthma patient.
AstraZeneca PLC AZN shares rallied 1.33% to £117.20 Thursday, on what proved to be an all-around great trading session for ...
AstraZeneca is extending its work with Immunai through a multiyear collaboration that aims to implement its ...
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...
Shares of AstraZeneca PLC AZN inched down 0.54% to £115.22 Tuesday, on what proved to be an all-around positive trading ...
The Zacks Daily presents the best research output of our analyst team. Today's Daily features new research reports on 16 ...
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, ...